重组干扰素α-2b联合阿昔洛韦治疗小儿传染性单核细胞增多症的效果及对免疫功能的影响  

Efficacy of Recombinant Interferon α-2b Combined with Acyclovir in the Treatment of Infectious Mononucleosis in Children and Its Influence on Immune Function

作　　者：陈燕燕 李墨 CHEN Yanyan;LI Mo(The Second People’s Hospital of Huishan District in Wuxi City,Jiangsu Province,Wuxi 214174,China;不详)

机构地区：[1]江苏省无锡市惠山区第二人民医院,江苏无锡214174

出　　处：《中国医学创新》2022年第19期71-74,共4页Medical Innovation of China

摘　　要：目的:探讨重组干扰素α-2b联合阿昔洛韦治疗小儿传染性单核细胞增多症(IM)的效果及对免疫功能的影响。方法:选取2019年3月-2021年3月无锡市惠山区第二人民医院收治的IM患儿108例,依据随机数字表法将其分为α-2b组(n=54)和阿昔洛韦组(n=54)。阿昔洛韦组给予5 mg/kg阿昔洛韦静滴治疗,3次/d,共10 d;α-2b组在对照组基础上给予2μg/kg重组干扰素α-2b雾化吸入治疗,2次/d,共10 d。比较两组临床症状、免疫功能(CD3^(+)、CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+))、治疗效果、复发及不良反应发生情况。结果:α-2b组退热、肝脾回缩、淋巴结缩小、肌酶复常时间均短于阿昔洛韦组(P<0.05)。治疗后1 d,两组CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)均高于治疗前,CD8^(+)低于治疗前,且α-2b组CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)均高于阿昔洛韦组,CD8^(+)低于阿昔洛韦组(P<0.05)。α-2b组治疗总有效率高于阿昔洛韦组,复发率低于阿昔洛韦组(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:重组干扰素α-2b联合阿昔洛韦可改善IM患儿临床症状、免疫功能,提高疗效,且安全性好。Objective:To discuss the efficacy of Recombinant Interferonα-2b combined with Acyclovir in the treatment of infectious mononucleosis(IM)in children and its influence on immune function.Method:A total of 108 children with IM in the Second People’s Hospital of Huishan District in Wuxi City from March 2019 to March 2021 were selected,they were divided intoα-2b group(n=54)and Acyclovir group(n=54)according to the random table.The Acyclovir group was given 5 mg/kg Acyclovir intravenously treatment,3 times a day,10 d,on the basis of the Acyclovir group,theα-2b group was given 2μg/kg Recombinant Interferonα-2b atomization inhalation treatment,twice a day,10 d.The clinical symptoms,immune function(CD3^(+),CD4^(+),CD8^(+),CD4^(+)/CD8^(+)),therapeutic efficacy,recurrence and adverse reactions were compared between two groups.Result:The time of fever,liver and spleen retraction,lymph node shrinkage and muscle enzyme normalization in theα-2b group were shorter than those in the Acyclovir group(P<0.05).At 1 d after treatment,the CD3^(+),CD4^(+),CD4^(+)/CD8^(+)in two groups were higher than those before treatment,the CD8^(+)were lower than those before treatment,and the CD3^(+),CD4^(+),CD4^(+)/CD8^(+)in theα-2b group were higher than those in the Acyclovir group,the CD8^(+)was lower than that in Acyclovir group(P<0.05).The total effective rate in theα-2b group was higher than that in the Acyclovir group,the recurrence rate was lower than that in the Acyclovir group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Recombinant Interferonα-2b combined with Acyclovir can improve the clinical symptoms and immune function of children with IM,it can improve curative effect,and it has good safety.

关 键 词：重组干扰素Α-2B 阿昔洛韦 小儿 传染性单核细胞增多症 免疫功能 

分 类 号：R725.1[医药卫生—儿科]